Leaflet LETROZOL ACCORD 2.5mg film-coated tablets

Product code:
W70021001
Quantity:
30
Indicated for:
breast cancer
Route of administration:
oral
Substance:
letrozole (aromatase inhibitor)
ATC
L02BG04 — Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Aromatase inhibitors
Letrozole is an aromatase inhibitor used for the treatment of hormone-dependent breast cancer in postmenopausal women. It works by reducing estrogen levels, thereby inhibiting the growth of hormone-sensitive tumors.

The medication is taken orally, usually once daily, as directed by a doctor. It is important to follow the treatment regimen to achieve the best results.

Side effects may include hot flashes, fatigue, joint pain, or osteoporosis. In rare cases, allergic reactions or liver disorders may occur.

Letrozole is not recommended for pregnant or breastfeeding women or patients with hypersensitivity to this medication.

General data about LETROZOL ACCORD 2.5mg

Substance:
letrozole
Date of latest medicines list:
01-06-2026
Product code:
W70021001
Concentration:
2.5mg
Pharmaceutical form:
film-coated tablets
Quantity:
30
Product type:
Generic medicine
Price:
88.68 RON
Prescription status:
P-6L — Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.

Marketing authorisation

Manufacturer:
ACCORD HEALTHCARE B.V. - TARILE DE JOS
Holder:
ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA
Number:
15279/2024/01
Shelf life:
3 years

Pharmaceutical forms available for letrozole

Compensation lists for LETROZOL ACCORD 2.5mg Accord

NHP 3 (C2) - NHP oncology

Price
88.68 RON
Copayment
88.68 RON
Patient
0.00 RON